LEXEO Therapeutics is a New York City-based clinical-stage gene therapy company, dedicated to developing disease-modifying treatments for genetic cardiovascular conditions and genetic conditions of the central nervous system (CNS). With a deep and diverse pipeline of adeno-associated virus (AAV)-based gene therapy candidates, LEXEO aims to address some of the most devastating genetically defined diseases affecting both rare and prevalent patient populations. Their current pipeline focuses on rare cardiovascular diseases, APOE4-associated Alzheimer’s disease, and CLN2 Batten disease.

Founded by a team of pioneering scientists, clinicians, and business leaders with extensive expertise in gene therapy, LEXEO applies cutting-edge science to tackle the underlying causes of diseases. Their mission is to transform healthcare and revolutionize society by developing meaningful gene therapies, regardless of disease prevalence. LEXEO is committed to pushing boundaries and delivering innovative solutions to resolve the burden of disease